Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 5/20 | 0.64 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490515 | 0.87 | SETD7 (0.68) | SETD7HTTCYP3A4KCNH2CHRM2 | |
| SCHEMBL490196 | 0.87 | SETD7 (0.48) | SETD7HTTCYP3A4KCNH2CHRM2 | |
| SCHEMBL490625 | 0.81 | SETD7 (0.60) | SETD7HTTCYP3A4KCNH2CHRM2 | |
| SCHEMBL2633229 | 0.81 | SLC6A4 (0.42) | SETD7TRPA1ALOX5KCNH2CYP2D6 | |
| SCHEMBL5905710 | 0.80 | SETD7 (1.00) | SETD7HTTCYP3A4KCNH2CHRM2 | |
| SCHEMBL490256 | 0.77 | SETD7 (0.76) | SETD7HTTCYP3A4KCNH2CHRM2 | |
| SCHEMBL5905649 | 0.75 | SETD7 (0.60) | SETD7HTTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL490195 | 0.74 | SETD7 (0.51) | SETD7HTTCYP3A4KCNH2CHRM2 | |
| SCHEMBL3138914 | 0.73 | KCNH2 (0.44) | SETD7KCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL3131643 | 0.73 | KCNH2 (0.56) | SETD7HTTCYP3A4KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2011-10-06 | — | — | US | disclosed |
| US-7982042-B2 | delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions;N-{2-[10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-yl]-phenyl}-acetamide | Janseen Pharmacautica NV (BE) | 2011-07-19 | — | — | US | disclosed |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-1644373-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003131-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | SETD7 4197/4885TRPA1 84/4885ALOX5 1363/4885 |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | SETD7 4197/4885TRPA1 84/4885ALOX5 1363/4885 |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | SETD7 4197/4885TRPA1 84/4885ALOX5 1363/4885 |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | SETD7 4197/4885TRPA1 84/4885ALOX5 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.